Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Overview
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Companies Involved in Therapeutics Development
Aeropharma Science Inc
Aurealis Therapeutics AG
ID Pharma Co Ltd
Momenta Pharmaceuticals Inc
RemeGen Ltd
Ribomic Inc
Zucero Therapeutics Ltd
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Drug Profiles
AUP-16 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DVC-10101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Inhibit FGF-2 for Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate FGF2 for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
necuparanib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oncolytic Virus to Activate FGF2 for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pixatimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RC-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TR-764 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Dormant Products
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Discontinued Products
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Product Development Milestones
Featured News & Press Releases
Jul 15, 2020: RIBOMIC announces dosing of first subject in RBM-007 phase 1 clinical trial for Achondroplasia
Feb 19, 2020: RIBOMIC announces first injection in the Phase 2 clinical trial of RBM-007 (TOFU Study) in subjects with wet age-related macular degeneration
Jun 19, 2019: Ribomic reports positive results from SUSHI study of RBM-007
Jun 03, 2019: Publication of a collaborative study with Keio University School of Medicine on the inhibitory effect of RBM-007 combition therapy on Lung Cancer
Sep 24, 2017: Aurealis Pharma to Present at Sachs Associates 17th Annual Biotech in Europe Forum Basel, September 26-27t h 2017
Apr 26, 2017: Aurealis Pharma to Discuss AUP-16 Clinical Development at the 27th European Wound Magament Association Annual Meeting, Amsterdam
Jan 02, 2017: Aurealis Pharma to Attend 9th Annual Partnering Conference - Biotech Showcase, San Francisco
Sep 23, 2016: Aurealis Pharma to Present at Sachs Associates 16th, Annual Biotech in Europe Forum Basel
Aug 04, 2016: Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Alysis
Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Fil Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO
May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting
Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
Sep 04, 2015: Aurealis Pharma Expands its Magement Team and Announces Opening of New Office In Basel Switzerland
Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Anaeropharma Science Inc, H2 2020
Pipeline by Aurealis Therapeutics AG, H2 2020
Pipeline by ID Pharma Co Ltd, H2 2020
Pipeline by Momenta Pharmaceuticals Inc, H2 2020
Pipeline by RemeGen Ltd, H2 2020
Pipeline by Ribomic Inc, H2 2020
Pipeline by Zucero Therapeutics Ltd, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020